Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBT Margin (2022 - 2025)

Historic EBT Margin for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to 362.73%.

  • Gossamer Bio's EBT Margin fell 258600.0% to 362.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 803.97%, marking a year-over-year decrease of 7364000.0%. This contributed to the annual value of 61.34% for FY2024, which is N/A changed from last year.
  • Latest data reveals that Gossamer Bio reported EBT Margin of 362.73% as of Q3 2025, which was down 258600.0% from 333.13% recorded in Q2 2025.
  • Gossamer Bio's 5-year EBT Margin high stood at 1698.73% for Q3 2022, and its period low was 397.03% during Q1 2025.
  • For the 4-year period, Gossamer Bio's EBT Margin averaged around 634.14%, with its median value being 242.37% (2024).
  • Data for Gossamer Bio's EBT Margin shows a peak YoY increase of -258600bps (in 2025) and a maximum YoY decrease of -3891200bps (in 2025) over the last 5 years.
  • Over the past 4 years, Gossamer Bio's EBT Margin (Quarter) stood at 1655.19% in 2022, then fell by -12bps to 1453.0% in 2023, then tumbled by -83bps to 242.37% in 2024, then tumbled by -250bps to 362.73% in 2025.
  • Its EBT Margin was 362.73% in Q3 2025, compared to 333.13% in Q2 2025 and 397.03% in Q1 2025.